Pith. sign in

REVIEW 3 major objections 6 minor 30 references

Molecular Determinants of Orthosteric-allosteric Dual Inhibition of PfHT1 by Computational Assessment

T0 review · 3 major / 6 minor · reviewed 2026-08-16 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read Molecular dynamics identifies the residues that control dual-site inhibition of the malaria transporter PfHT1 and reproduces experimental potency trends.

desk verdict Solid computational follow-up with a useful residue-level map, but the allosteric rankings ride on a forced pocket closure that needs independent validation. read the letter →

arxiv 2504.18559 v1 pith:YQBBMLES submitted 2025-04-18 physics.bio-ph cond-mat.softphysics.chem-phq-bio.BM

Decheng Kong , Jinlong Ren , Zhuang Li , Guangcun Shan , Zhongjian Wang , Ruiqin Zhang , Wei Huang , Kunpeng Dou This is my paper · ORCID
classification physics.bio-phcond-mat.softphysics.chem-phq-bio.BM
keywords PfHT1antimalarialdrugresistanceorthosteric-allostericdualinhibitionmoleculardynamicsbindingfreeenergyper-residuedecompositionmutationanalysiscarbohydrateinhibitors
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This paper uses molecular dynamics simulations to explain why carbohydrate-based inhibitors of the malaria transporter PfHT1 differ so widely in potency, even when they share the same sugar core and tail group. The authors compute binding free energies for ten dual-site inhibitors divided into three groups by linker length, tail size, and sugar type, and report that the computed energies reproduce the experimental IC50 ordering in each group. Per-residue energy decomposition then ranks the residues that matter most: Lys51, Leu47, and Val443 dominate allosteric-site binding, with Asp447 stabilizing the pocket, while orthosteric-site residues control sugar-specific recognition. Mutation simulations validate the rankings, with one clear exception: a fructose derivative binds more tightly when orthosteric residues are mutated to alanine because the mutation changes its pose. If these rankings are right, they give a residue-level map for designing dual-site antimalarial inhibitors that can circumvent resistance.

What carries the argument

The rankings come from two linked computational devices. First is the per-residue decomposition of the MM-GBSA binding free energy (molecular mechanics with generalized Born and surface-area solvation, a standard end-state estimate of binding affinity), which sums each amino acid's contribution and produces the residue rankings. Second is the reversed allosteric communication protocol, in which steered molecular dynamics pulls the TM1e helix toward the inhibitor and WHAM (weighted histogram analysis) yields the potential of mean force; because no allosteric pocket formed in ordinary forward simulations, this forced-closure trajectory is the basis for identifying Lys51 as pocket-forming and the Lys51–Asp447 salt bridge as pocket-stabilizing.

What would settle it

Determine the co-crystal structure of PfHT1 with HTI9 and check whether the allosteric pocket is closed with a Lys51–Asp447 salt bridge matching the simulated forced-closure conformation; if the crystal shows an open or differently shaped pocket, the residue rankings built on that trajectory are not representative. A complementary check would measure IC50 values for Lys51Ala and Asp447Ala mutants against HTI8 or HTI9 and compare the predicted affinity losses.

Watch

Extended reading notes

Core claim

The paper's central claim is that MM-GBSA binding free energies from molecular dynamics reproduce the experimentally observed potency order of the published PfHT1 dual inhibitors, and that per-residue decomposition identifies which residues carry each part of inhibitor binding. For the allosteric pocket, Lys51, Leu47, and Val443 are the dominant determinants, while the Lys51–Asp447 interaction gates pocket closure and stabilization. For the orthosteric pocket, residues including Asn311, Asn435, Gln305, Gln306, Trp390, and Phe403 discriminate the sugar moiety. Since no allosteric pocket formed spontaneously after HTI9 reached the orthosteric site in forward simulations, the authors deliberately pulled helix TM1e toward the inhibitor to close the pocket, treating this as reversed allosteric communication, and used pocket volume and PMF profiles to argue that Lys51 forms the pocket and Asp447 stabilizes it. Mutating the ranked sites to alanine generally lowers calculated affinity, with the outlier that fructose gains affinity on orthosteric mutation because its binding pose shifts and new residues become available.

Load-bearing premise

The allosteric-pocket rankings assume that the pocket shape made by pulling one protein helix toward the inhibitor, done only after no allosteric pocket formed on its own, is the same shape a real inhibitor would create.

Editorial extensions

If this is right

  • Allosteric-site design should aim at hydrophobic contacts with Lys51, Leu47, and Val443, and should preserve the Lys51–Asp447 interaction to keep the pocket closed.
  • The nonmonotonic linker-length dependence (best near n=9) follows the summed contribution of the three allosteric residues rather than pocket volume, so linker design should be tuned against those contacts.
  • Mutations at orthosteric residues will not weaken all sugar-based inhibitors equally: fructose derivatives are predicted to gain affinity through pose change, suggesting a scaffold for resistant backgrounds.
  • The per-residue maps provide concrete residue-level targets for designing one-molecule dualsteric compounds that occupy both the orthosteric and allosteric sites.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • Editorial inference: if the forced-closure pocket is the true cryptic allosteric site, a compound that pre-stabilizes the Lys51–Asp447 salt bridge before its sugar reaches the orthosteric site should bind more potently, since the PMF barrier to pocket closure would be lowered.
  • Editorial inference: the mutation results imply a testable resistance scenario in which parasites carrying orthosteric-site mutations that impair glucose transport become selectively vulnerable to fructose-based inhibitors, because those compounds bind better in the mutant background.
  • Editorial inference: the reversed-communication protocol is a transferable way to search for cryptic allosteric pockets in other transporters, but its residue rankings would need structural validation before being used for drug design.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

3 major / 6 minor

Summary. The manuscript presents molecular dynamics (MD) simulations of the Plasmodium falciparum hexose transporter 1 (PfHT1) bound to dual orthosteric/allosteric inhibitors. Ten inhibitors are classified into three groups according to linker length, tail-group size, and sugar moiety, and the authors compute MM-GBSA binding free energies, pocket volumes, SMD/WHAM PMF profiles for allosteric pocket formation, and per-residue free energy decompositions. The central claim is that the computed free energies reproduce published experimental IC50 trends, and that per-residue decomposition, combined with alanine mutation analysis, reveals the key molecular determinants, with Lys51, Leu47, Val443, and Asp447 at the allosteric site and several residues at the orthosteric site. The paper also reports an outlier behavior for a fructose derivative, whose binding affinity is enhanced when orthosteric residues are mutated.

Significance. If the results are reliable, the paper offers a computational protocol for ranking residue-level determinants in dual-site inhibition and generates a testable prediction about fructose-derived inhibitors being sensitized by orthosteric mutations. The work has several strengths: it benchmarks against published IC50 data without fitting parameters, uses explicit membrane and solvent environments, performs three replicas per system, and cross-validates the key-residue hypothesis with multiple independent analyses (PMF, pocket volume, decomposition, and mutation studies). The significance is, however, conditional on the allosteric pocket being sampled without a potentially biasing steering protocol and on the statistical reliability of the reported free-energy differences, neither of which is established in the present manuscript.

major comments (3)
  1. [3.1 (Figs. 2, 3)] The allosteric pocket on which all residue rankings rest is generated by an external bias. The authors state that 'no allosteric pocket is found to form after HTI9 arrives at the orthosteric site', and then switch to a 'reversed allosteric communication' protocol in which the TM1e helix is pulled toward the inhibitor (Section 2.1, third paragraph). All subsequent allosteric-site analyses, including pocket-volume comparisons (Figs. 4(b) and 7(b)), per-residue decompositions (Figs. 5, 6, 8, 9), PMF profiles (Fig. 2(d)), and mutation validations (Fig. 11), use conformations produced by this SMD bias. The paper does not show that an unbiased simulation visits a similar closed-pocket geometry, and it does not compare the forced pocket with the experimentally characterized allosteric site of PfHT1, where the native ligand C3361 is bound in the crystal structures 6M2L/6M20. Therefore the key-residue rankings and PMF conclusions are conditional on the unvalidated assumption that the steered pathway corresponds to the physiologically relevant binding-competent state.
  2. [2.1 and 3.2 (Figs. 4, 7, 10)] The claimed agreement with experimental IC50 data is presented qualitatively, with no error bars, correlation coefficients, or significance tests. Although the text states that 'three parallel simulations were performed for all cases' (Section 2.1, first paragraph), the reported ΔGbinding values, pocket volumes, PMFs, and per-residue decomposition energies appear without standard deviations or confidence intervals. Several differences that support the main claims are visually small; for example, the ΔGbinding difference between HTI8 and HTI10 in Fig. 4(c) is modest, as is the difference between Glu-O3 and Glu-O2 in Fig. 10(c). Without per-replica statistics and a rank-correlation measure (e.g., Spearman's ρ with a p-value), the statement in the Introduction of a 'high correlation' with experimental data is not quantitatively supported.
  3. [3.2 (Figs. 4(c), 7(c), 10(c))] The comparison of MM-GBSA binding free energies with quantities labeled ΔGexp=RTlnIC50 is conceptually problematic. IC50 is a functional assay readout, not an equilibrium binding constant, and converting it to an energy via RTlnIC50 introduces an arbitrary offset and assumes a constant relationship between IC50 and binding affinity across chemically diverse compounds. The manuscript should state this approximation explicitly and, for robustness, compare computed ranks with experimental ranks rather than plotting both quantities on the same energy scale, or should clearly indicate that only the trend, not the absolute values, is meaningful.
minor comments (6)
  1. [Abstract] The phrase 'Our binding free energy analysis capture' should be 'Our binding free energy analysis captures'; also 'essential trend' is used twice (abstract and Introduction) and could be replaced with 'overall trend' for clarity.
  2. [2.1, third paragraph] The sentence describing the SMD protocol is ambiguous: it mentions 'constant-velocity (0.1 nm/μs)' pulling but then says 'by an umbrella potential,' which are two different approaches. Please clarify whether this is a single constant-velocity pull or an umbrella-sampling setup.
  3. [Table 2] The blank entries in Table 2 (Ile310 for Glu-O2, Phe403 for Glu-O2 and Fru, Trp436 for Fru) are not explained; please indicate whether these are non-favorable interactions, interactions below a threshold, or missing values, and add a footnote.
  4. [3.2.3] The cross-reference '(Figs. 10 (d) and (e))' for the free energy decomposition appears incorrect: Fig. 10(d) is labeled 'Experimental IC50 trend,' while the decomposition is shown in Fig. 10(e). Please fix the reference.
  5. [3.1, final paragraph] The sentence 'This is in line with the experimental findings' regarding Lys51 and Asp447 is too broad; the cited experimental work identifies the allosteric ligand and overall pocket, not necessarily a residue-level mechanism, so the specific experimental observation being compared should be stated.
  6. [Throughout] No data availability statement or reproducibility details (topology files, input scripts, MM-GBSA parameters such as dielectric constants and entropy treatment) are provided; at least the MM-GBSA setup should be reported in the Methods or Supplementary Information.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: computed affinities are benchmarked against external IC50 data without parameter fitting, and key-residue ranking is an independent decomposition rather than a fitted prediction.

full rationale

The paper's central claim is that MM-GBSA binding free energies reproduce the trend of published experimental IC50 data and that per-residue decomposition identifies key determinants, subsequently probed by in silico mutation analysis. No parameter is fitted to the IC50 values; the comparison is a direct benchmark against external experimental data. The per-residue decomposition is a physical partitioning of the calculated binding free energy, and the mutation analysis is a separate computation on modified systems, not a restatement of the decomposition. The 'reversed allosteric communication' protocol is a methodological choice cited from prior literature, not an unverified uniqueness theorem imported from the authors. The paper candidly states that the forward allosteric-communication simulation did not form an allosteric pocket, and this is a limitation regarding conformational relevance, not a circular reduction of the derivation to its inputs. No equation reduces to another by construction, and no fitted parameter is renamed as a prediction.

Assumptions & free parameters 0 free parameters · 5 assumptions · 0 invented entities

The model is built from experimental crystal structures and benchmarked against experimental IC50 data; the free energy calculations introduce no fitted parameters. The main unvalidated inputs are the protocol choices: reversed allostery, 100 ns sampling, MM-GBSA approximation, and alanine-mutation fidelity.

assumptions (5)
  • domain assumption The crystal structures 6M2L and 6M20 represent the relevant physiological conformations of PfHT1 and its inhibitor complexes.
    Section 2.1 builds the models by removing native ligands from these PDB structures; if these conformations are not the solution-state binding-competent states, all downstream docking and MD results inherit that error.
  • domain assumption MM-GBSA binding free energies correlate monotonically with experimental IC50 values across chemically distinct inhibitor groups.
    Section 3 compares ΔGbinding to ΔGexp = RT ln IC50 for each group; the entire validation rests on this correlation holding for carbohydrate inhibitors on PfHT1, which is assumed rather than proven.
  • ad hoc to paper The reversed allosteric communication protocol (ligand at orthosteric site drives closure of the allosteric pocket) reproduces the physiologically relevant allosteric mechanism.
    Section 3.1 states no allosteric pocket formed in the forward direction, and the authors then pulled the TM1e helix toward the inhibitor; the resulting pocket is used to define the allosteric-site residues.
  • domain assumption 100 ns MD per replicate is sufficient to sample the relevant binding conformations and converged free energies.
    Section 2.1 uses 100 ns production runs with three replicates; no convergence analysis or block-error estimates are shown.
  • domain assumption In silico alanine mutations faithfully report the effect of the mutation on inhibitor binding affinity.
    Section 3.3 interprets changes in computed ΔGbinding upon mutation as validation of residue importance; no experimental mutagenesis data is provided.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Molecular Determinants of Orthosteric-allosteric Dual Inhibition of PfHT1 by Computational Assessment." pith.science (2026). https://pith.science/paper/YQBBMLES

@misc{pith2026250418559,
  author       = {Pith},
  title        = {Pith review of: Molecular Determinants of Orthosteric-allosteric Dual Inhibition of PfHT1 by Computational Assessment},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/YQBBMLES}},
  note         = {Machine review of arXiv:2504.18559}
}
read the original abstract

To overcome antimalarial drug resistance, carbohydrate derivatives as selective PfHT1 inhibitor have been suggested in recent experimental work with orthosteric and allosteric dual binding pockets. Inspired by this promising therapeutic strategy, herein, molecular dynamics simulations are performed to investigate the molecular determinants of co-administration on orthosteric and allosteric inhibitors targeting PfHT1. Our binding free energy analysis capture the essential trend of inhibitor binding affinity to protein from published experimental IC50 data in three sets of distinct characteristics. In particular, we rank the contribution of key residues as binding sites which categorized into three groups based on linker length, size of tail group, and sugar moiety of inhibitors. The pivotal roles of these key residues are further validated by mutant analysis where mutated to nonpolar alanine leading to reduced affinities to different degrees. The exception was fructose derivative, which exhibited a significant enhanced affinity to mutation on orthosteric sites due to strong changed binding poses. This study may provide useful information for optimized design of precision medicine to circumvent drug-resistant Plasmodium parasites with high efficacy.

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

30 extracted references · 29 canonical work pages

  1. [1]

    Geneva: World Health Organization; 2024

    World malaria report 2024: addressing inequity in the global malaria response. Geneva: World Health Organization; 2024

    work page 2024

  2. [2]

    D. Ni, Y . Li, Y . R. Qiu, J. Pu, S. Y . Lu, and J. Zhang, Trends Pharmacol. Sci. 41, 336–348 (2020)

    work page 2020

  3. [3]

    J. Y . Zha, J. X. He, C. W. Wu, M. Y . Zhang, X. Y . Liu, and J. Zhang, Chem. Soc. Rev. 52, 8651–8677 (2023)

    work page 2023

  4. [4]

    N. Li, G. D. Zheng, L. L. Fu, N. Liu, T. Chen, and S. Y . Lu, Drug Discov. Today 29, 104141 (2024)

    work page 2024

  5. [5]

    Y . L. Liu, M. Z. Zhang, H. Jang, and R. Nussinov, Chem. Sci. 15, 1003–1017 (2024)

    work page 2024

  6. [6]

    Y . R. Qiu, X. L. Yin, X. Y . Li, Y . H. Wang, Q. Fu, R. H. Huang, and S. Y . Lu, Pharmaceutics 13, 747 (2021)

    work page 2021

  7. [7]

    L. P. Hu, S. M. Shi, X. M. Song, F. L. Ma, O. L. Ji, B. H. Qi, Eur. J. Med. Chem. 265, 116074 (2024)

    work page 2024

  8. [8]

    Zhang, M

    H. Zhang, M. S. Zhu, M. Z. Li, D. Ni, Y . H. Wang, L. P. Deng, K. Du, S. Y . Lu, H. Shi, and C. Cai, Front. Pharmacol. 13, 862504 (2022)

    work page 2022

Show all 30 references
  1. [9]

    Fischer, F

    A. Fischer, F. Häuptli, M.A. Lill, M. Smieško, J. Chem. Inf. Model. 61, 1001−1009 (2021)

    2021

  2. [10]

    Jiang, Y

    X. Jiang, Y . F. Yuan, J. Huang, S. Zhang, S. C. Luo, N. Wang, D. B. Pu, N. Zhao, Q. X. Tang, and K. Hirata, Cell 183, 258 (2020)

    2020

  3. [11]

    Huang, Y

    J. Huang, Y . F. Yuan, N. Zhao, D. B. Pu, Q. X. Tang, S. Zhang, S. C. Luo, X. K. Yang, N. Wang, and Y . Xiao, Proc. Natl. Acad. Sci. U.S.A. 118, e2017749118 (2021)

    2021

  4. [12]

    N. Wang, S. Zhang, Y . F. Yuan, H. W. Xu, E. Defossa, H. Matter, M. Besenius, V . Derdau, M. Dreyer, and N. Halland, Nat. Commun. 13, 2632 (2022)

    2022

  5. [13]

    Kapoor, J

    K. Kapoor, J. S. Finer-Moore, B. P. Pedersen, L. Caboni, A. Waight, R. C. Hillig, P. Bringmann, I. Heisler, T. Mueller, and H. Siebeneicher, Proc. Natl. Acad. Sci. U.S.A. 113, 4711–4716 (2016)

    2016

  6. [14]

    Webb and A

    B. Webb and A. Sali, Curr Protoc Bioinform. 54, 5.6.1–5.6.37 (2016)

    2016

  7. [15]

    Trott and A

    O. Trott and A. J. Olson, J. Comput. Chem. 31, 455–461 (2010)

    2010

  8. [16]

    Eberhardt, D

    J. Eberhardt, D. Santos -Martins, A. F. Tillack, and S. Forli, J. Chem. Inf. Model. 61, 3891–3898 (2021)

    2021

  9. [17]

    S. Park, Y . K. Choi, S. Kim, J. Lee, and W. Im, J. Chem. Inf. Model. 61, 5192−5202 (2021)

    2021

  10. [18]

    W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey, and M. L. Klein, J. Chem. Phys. 79, 926 (1983)

    1983

  11. [19]

    Huang, S

    J. Huang, S. Rauscher, G. Nawrocki, T. Ran, M. Feig, B. L. de Groot, H. Grubmueller, and A. D. MacKerell Jr., Nat. Methods. 14, 71–73 (2017)

    2017

  12. [20]

    H. M. Khan, A. D. MacKerell Jr., and N. Reuter, J. Chem. Theory Comput. 15, 7– 12 (2019)

    2019

  13. [21]

    M. J. Abraham, T. Murtola, R. Schulz, S. Páll, B. Hess, and E. Lindahl, SoftwareX. 1, 19–25 (2015)

    2015

  14. [22]

    S. Páll, M. J. Abraham, C. Kutzner, B. Hess, and E. Lindahl, Lect. Notes Comput. Sci. 8759, 3–27 (2015)

    2015

  15. [23]

    Kumar, J

    S. Kumar, J. M. Rosenberg, D. Bouzida, R. H. Swendsen, and P. A. Kollman, J. Comput. Chem. 16, 1339–1350 (1995)

    1995

  16. [24]

    T. W. Allen, O. S. Andersen, and B. Roux, Biophys. Chem. 124, 251–267 (2006)

    2006

  17. [25]

    M. S. Valdés-Tresanco, M. E. Valdés-Tresanco, P. A. Valiente, and E. Moreno, J. Chem. Theory Comput. 17, 6281–6291 (2021)

    2021

  18. [26]

    Y . Yang, Z. Wang, L. Wang, Q. Wang, R. Tang, S. Xiang, Q. Deng, T. Hou, and H. Sun, Research 2023, 0170 (2023)

    2023

  19. [27]

    Zhang, J

    W. Zhang, J. Xie, L. Lai, Correlation Between Allosteric and Orthosteric Sites. Adv. Exp. Med. Biol. 1163, 89–105 (2019)

    2019

  20. [28]

    J. G. Fan, Y . Q. Liu, R. Kong, D. Ni, Z. T. Yu, S. Y . Lu, and J. Zhang, J. Med. Chem. 64, 17728–17743 (2021)

    2021

  21. [29]

    D. Ni, J. C. Wei, X. H. He, A. U. Rehman, X. Y . Li, Y . R. Qiu, J. Pu, S. Y . Lu, and J. Zhang, Chem. Sci. 12, 464–476 (2021)

    2021

  22. [30]

    A. A. Qureshi, A. Suades, R. Matsuoka, J. Brock, S. E. McComas, E. Nji, L. Orellana, M. Claesson, L. Delemotte, and D. Drew, Nature. 578, 321 (2020)

    2020

Pith tools

Reviewed August 16, 2026 · model on record in the stance chip above.